The placenta synthesizes a number of cytokines and growth factors that are involved in the establishment, maintenance or regulation of pregnancy. Included are interferons, placental lactogens, other members of the growth hormone/prolactin gene family, leptin, and an array of angiogenic growth factors. While their roles in pregnancy differ, in their absence pregnancy is either lost or compromised. Therefore an understanding of the cell-specific transcriptional regulation of these genes is imperative if we are ever to alter their expression to benefit pregnancy progression. Our understanding of transcriptional regulation in the placenta is still in its infancy, and there appears to be considerable divergence in the transcriptional regulation of these genes between species, as well as between the various cytokine genes being examined. For example, while there are some commonalities in the regulation of human, rodent and ruminant placental lactogens, there are differences that require the study of placental lactogen gene regulation across species. However, one common theme that is emerging with the angiogenic growth factors, such as vascular endothelial growth factor and the angiopoietins, is the transcriptional control of these genes by oxygen tension within the placenta. Examination of transcriptional regulation in normal and compromised pregnancies will provide additional insight in this area.
Introduction
Intrauterine growth restriction (IUGR) is a significant cause of increased infant mortality and morbidity, affecting up to 8 % of all pregnancies.
While IUGR fetuses can be categorized into symmetric or asymmetric growth patterns, the majority of cases present an asymmetric pattern of growth. The aetiologies for asymmetric IUGR are numerous and heterogeneous, but are often associated with abnormalities in placental structure and function. A number of placental structural abnormalities have been associated with IUGR pregnancies, including decreases in villous number, diameter and surface area, as well as decreases in arterial number, lumen size and branching. These abnormalities can adversely affect placental function, and ultimately deprive the fetus of the nutrients required for optimal growth. Therefore, generating an understanding of the transcriptional regulation of genes involved in placental development and function will provide new insight into the development and progression of IUGR pregnancies.
Regulation of placental development
The process of implantation and placentation involves a plethora of angiogenic growth factors, cell-adhesion molecules, cytokines and growth factors, extracellular matrix metalloproteinases, hormones and transcription factors. The exact role for most of these within the placenta is still unknown, and little is known about the role of specific transcription factors required for normal placental development. However, functional disruption of the genes encoding several transcription factors has provided insight into their role in murine placenta development. Mash-2, a basic helix-loophelix (bHLH) transcription factor, is required for spongiotrophoblast cell development [l] , and in its absence mice die at embryonic day 10 due to the absence of placental spongiotrophoblasts. Another b H L H protein, Handl, is required for the differentiation of trophoblast giant cells, and in its absence embryonic devel-opment is arrested at day 7.5 [2] . While both of these bHLH proteins, Mash-2 and Handl, are required for normal placental development, it is not known what genes they interact with. In contrast, GCM-1 (glial cells missing-1) appears to be involved in placenta-specific expression of the human aromatase and leptin genes [3] . GCM-1 is expressed by murine chorionic trophoblast cells within the developing chorionic plate and at sites of chorioallantoic folding, and disruption of this gene results in embryonic mortality at day 10 due to absence of the placental labyrinth [4] . The zincfinger proteins GATA-2 and -3 are expressed in trophoblast giant cells ; disruption of these genes results in arrested development at mid gestation and depressed mouse placental lactogen-I (PL-I) gene expression [S] . In addition to these transcription factors, the transcriptional regulation of a variety of genes expressed by the placenta has been examined. Among these are the PLs. In primates, the P L genes are derivatives of the ancestral growth hormone gene, whereas in rodents and ruminants the PLs were derived from the ancestral prolactin gene [6] . Since the structure of each P L varies by species, as does placental anatomy and the cell of origin, comparing the transcriptional regulation of these genes may provide insight into placenta-cell specific control.
Transcriptional control of PLs
Tissue-specific transcriptional regulation has been reasonably well defined for the human P L (hPL) and rodent PL-I genes. The proximal 500 bp of 5' flanking sequence for all the human growth hormone and hPL genes share > 90% identity, and all of these promoters are capable of stimulating pituitary-specific transcription [7] . In contrast with pituitary expression, trophoblast cells ( Figure 1A ) utilize a ubiquitous SP-1 site [8], two activator protein-2 (AP-2) sites [9] and a trophoblast-specific initiator element (InrE) located within this proximal region [lo] . However, these sites, along with the TATA box, only function as general enhancers, which nucleate the preinitiation complex for RNA polymerase 11. The true placental-specific enhancer element(s) are localized to a 138 bp region [CSEn (chorionic somatomammotropin gene enhancer)] x 2.2 kb 3' of the last P L gene (hPL-111), for which several DNA-protein interactions have been described [7, . One protein, TEF-1 (transcriptional enhancer factor-1), was originally thought to be the specific trans-acting factor [7] . However, later studies revealed that TEF-1 reduces transactivation by inhibiting the formation of the preinitiation complex [14] . Another distinct protein (CSEF-1; chorionic somatomammotropin gene enhancer factor-1) binds to the same cis-acting element, with the same affinity as TEF-1, thus potentially creating a positive/negative transcriptional regulatory site [15] . However, no single ciselement within the CSEn is able to individually initiate placental-specific transcription from the hPL promoter. In addition to the already complex design of downstream enhancers, two orientationdependent pituitary silencer factors (PSFs) and -569 bp confers trophoblast giant cellspecific transcription in transgenic mice [20] . The region responsible was identified as -1778 to -1471 bp, using transgenic mice and Rcho-1 cells, and included two cis elements involved in trophoblast-specific expression [21] . A similar region in the rat PL-I1 gene (-1793 to -1729 bp), responsible for activation in Rcho-1 cells, includes AP-1-and Ets-binding sites [22] . Thus regulation of hPL and rodent PL-I and -11 gene transcription appears to differ dramatically with regard to the cis elements involved and their relative genomic locations.
Our research focuses on the transcriptional regulation of ovine PL, which appears to have some similarities to both mouse PL and h P L transcription. DNase I protection analysis of 1.1 kb of ovine PL gene 5'-flanking sequence identified 19 footprints [23] . While trophoblast cell-specific activity was conferred by the proximal 1.1 kb region, maximal activity ( Figure 2A ) was retained within the proximal 383 bp of 5'-flanking sequence [23] . Within the proximal 124 bp region reside two GATA elements that interact with GATA-2, and a functional AP-2 element [23] . Immunohistochemistry revealed AP-2a within ovine chorionic binucleate cells, and screening an ovine placental cDNA library identified three splice variants of AP-2a. Two of the splice variants were able to stimulate transcriptional activity through the ovine PL promoter ( -124 bp), whereas the third did not, although it was capable of interacting with the element. Additionally, a unique cis-acting element within the proximal 124 bp (FP-3; Figure 2B ), identified by mutational analysis, interacts with the Pura to stimulate transcriptional activity. A functional Ebox was also identified at -163 bp [23] (Figure 2A) . A previously undefined element (GAGGAG) resides in both footprints, and mutation of either significantly reduces activity [23] . However, further analysis of these footprints indicates that there may be multiple protein-DNA interactions Schematic representation of the interactions that have been defined so far for the six DNase footprints (FP-I to FP-6) that reside within the proximal 383 bp. These include binding Sites for AP-2, GATA-2 and Pura, an E-box capable of binding bHLH proteins, and two previously undefined elements within FP-5 and FP-6. The apparent molecular masses (kDa) of the factor and/or factors that bind FP-5 and -6 are designated within the schematic of each.
within FP-5, and a single 140 kDa protein interacts with FP-6 ( Figure 2B ). Thus it is obvious that the regulation of human, rodent and sheep PL genes may differ considerably, while retaining some common features. Although it is not feasible in humans, use of both in vitro and in vivo approaches to examine transcriptional regulation of genes expressed by the placenta will ultimately define the necessary components.
Mechanisms of insufficient placental development
During normal human pregnancy, extravillous trophoblast (EVT) cells migrate along and invade the spiral artery vessel walls within the decidua and myometrium, but in pregnancies complicated by pre-eclampsia and/or IUGR, this invasion is largely restricted to the decidual portion of the spiral arteries [21-261. A number of factors have been associated with EVT invasion, including angiogenic growth factors and their respective receptors. A number of angiogenic growth factors have been identified in human placenta, including basic fibroblast growth factor [27] , hepatocyte growth factor [28] , placenta growth factor (PlGF) [29, 30] and vascular endothelial growth factor (VEGF) [29, 30] . There are several receptors capable of binding the various isoforms of VEGF and PlGF that have been described, including fms-like tyrosine kinase-1 (Flt-1; also known as VEGFR-I)
[31], a soluble form of Flt-1 [31], kinase insert domain-containing receptor (KDR ; also known as VEGFR-2) [31], and neuropilin-1 and -2 [32] .
While VEGF expression occurs in the villous trophoblast [30] , expression of PlGF has been localized to the villous syncytiotrophoblast [29, 30] . Both KDR and Flt-1 are expressed in placental villous endothelium [33] , but Flt-1 is also expressed in the EVT [34] . The Flt-1 receptor binds homodimers of VEGF, homodimers of PlGF or VEGF/PlGF heterodimers, whereas the KDR receptor binds only VEGF homodimers or VEGF/PlGF heterodimers [31] . When VEGF binds to the KDR receptor, but not when it binds to the Flt-1 receptor, efficient mitogenic and chemotactic responses occur with endothelial cells; the lack of a potent mitogenic response following binding of PlGF to Flt-1 led to the suggestion that Flt-1 is ineffective in mediating endothelial cell mitogenesis [3 11 . However, the presence of functional Flt-1 receptors on normal human trophoblasts suggests that binding of VEGF or PlGF to trophoblast Flt-1 may play a role in trophoblast invasion and differentiation [29, 34] . Supporting this hypothesis is the fact that early placental development occurs in a hypoxic environment [35] , a known stimulator of VEGF expression. Indeed, VEGF expression by placental tissues is up-regulated by hypoxia [29] and down-regulated by hyperoxia [29] . This has led to the examination of VEGF/PlGF in preeclamptic and IUGR pregnancies. In cases of utero-placental hypoxia [36] , where maternal oxygenation is normal, but an impaired uteroplacental circulation results in placental and fetal hypoxia with preserved end diastolic flow in the umbilical arteries, VEGF expression is increased and PlGF expression is reduced [37] . However, in cases of post-placental hypoxia [36] , where the fetus is hypoxic with absent end-diastolic flow in the umbilical arteries, the placental villi are believed to be chronically exposed to greater oxygen tension or 'placental hyperoxia', and VEGF expression is reduced and PlGF expression is increased [38] .
Hypoxic regulation of VEGF expression is mediated at both the transcriptional and posttranscriptional levels (Figure 3) . Increased VEGF mRNA stability during low oxygen tension is an important post-transcriptional response [39] . A hypoxia stability region in the 3'-untranslated region of the VEGF mRNA is bound by heterogeneous nuclear ribonucleoprotein L (hnRNP L), stabilizing the mRNA [39] and thereby increasing its half-life. Additionally, hypoxia-inducible factor-1 (HIF-1) is a bHLH transcription factor comprising two subunits (HIF-la and HIF-1B) that interacts with a hypoxic response element (HRE) in genes induced by hypoxia [40] . HIF-lB is constitutively expressed, whereas HIF-la is regulated by targeted proteolysis by the von Hippel-Lindau tumour suppressor gene product (pVHL) [41] . In the presence of oxygen ( Figure  3 ), HIF-la is degraded [41] , but under hypoxic conditions it is stabilized, allowing functional HIF-1 to act via the HRE in genes such as that encoding VEGF. While the expression of hnRNP L and HIF-la have not been examined in preeclamptic or IUGR placentas, HIF-la expression was found to be high at 5-7 weeks of gestation, decreasing around 9 weeks, when placental 0, tension is believed to increase; HIF-la was absent at 11-14 weeks [42] . Additionally, these investigators [42] found expression of transforming growth factor 83 (TGFp3) to parallel that of HIF-1 a, and treatment of placental villous explants with H I F -l a antisense oligonucleotides inhibited the expression of both H I F -l a and TGFD3. From these results and others, these investigators [43] suggested that the developmental increase in placental 0, tension reduces H I F -l a expression, which in turn reduces TGFD3 expression, thereby removing the inhibition by TGFB3 of trophoblast differentiation along the invasive pathway. In addition, one must consider the downstream effects of VEGF and PlGF that might influence placental circulation. Expression of endothelial nitric oxide synthase (eNOS) [44] and angiopoietin 2 (Ang2) [45] is stimulated by VEGF. In final-trimester human IUGR pregnancies, eNOS expression within the syncytiotrophoblast is increased [46] . However, this may be a compensatory response to improve blood flow within the IUGR placenta. This does not fit with the reports of depressed VEGF expression in term IUGR placentas [38] , but is in agreement with the report of enhanced VEGF levels in human IUGR placentas [37] . Both hypoxia and VEGF stimulate Ang2 expression [45] , and Ang2 stimulates the release of nitric oxide from human trophoblast cells in witro [47] . Angl has been localized in the cyto/syncytiotrophoblast bilayer in first-trimester human placenta [47] , Ang2 was found in the cytotrophoblast layer [47] or in the syncytiotrophoblast [48] , and their common receptor (Tie2) was found in the cyto/syncytiotrophoblast bilayer [47] and in endovascular invasive trophoblasts [48] . While Angl acts synergistically with VEGF [49] to stimulate angiogenesis, Ang2 is an antagonist to Angl, and in the absence of VEGF it is thought to destabilize or regress blood vessels [SO] . In severe IUGR placentas at term [47] , Ang2 mRNA concentrations were not different from those in normal placenta, but the amount of Ang2 protein appeared to be significantly decreased. One caveat to the studies on eNOS and Ang2 in IUGR pregnancies, as well as the studies examining VEGF and PlGF in IUGR pregnancies, is that samples have been collected during the last trimester or at term. Consequently, while the results obtained are indicative of what is occurring during late gestation, they do not adequately address the progression or development of an IUGR pregnancy.
Conclusion
While there are numerous cytokines and growth factors known to be involved in placental development, we understand the regulation of very few. In most cases in which transcriptional regulation within the placenta has been examined, regulation results from a combinatorial arrangement of transcription factors that often vary by species. Considerable work is still needed before we have the knowledge with which to alter gene expression within the placenta to improve pregnancy outcomes.
Introduction
Prolactin (PRL) is a hormone secreted by the anterior pituitary gland. It was originally identified by its ability to stimulate the development of
